ABBV · News · 20261106N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-11-06 · Importance 52 · Surprise 42 · In source text
Japan-based Nxera Pharma signed an exclusive global licensing agreement with AbbVie for its EP4 agonist program, including candidate NXE0033744 for inflammatory bowel disease. AbbVie will pay $100 million upfront, and Nxera is eligible for up to $1.37 billion in development and commercial milestone payments, plus tiered royalties. The agreement gives AbbVie worldwide rights to develop and commercialize the candidate; no payment schedule or timeframe was reported.
Key facts
- Under the licensing agreement, Nxera is eligible for up to an additional $1.37 billion in development and commercial milestone payments, plus tiered royalties. source
- AbbVie entered an exclusive global licensing agreement with Nxera Pharma for its EP4 agonist program, including NXE0033744, for inflammatory bowel disease. source
- AbbVie received exclusive worldwide rights to develop and commercialize NXE0033744 for IBD. source
- Under the licensing agreement, Nxera will receive an upfront payment of $100 million from AbbVie. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | contingent | -0.1% | Under the licensing agreement, Nxera is eligible for up to an additional $1.37 billion in development and commercial milestone payments,… |
| cash | negative | committed | -0.1% | Under the licensing agreement, Nxera will receive an upfront payment of $100 million from AbbVie. |